<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02547493</url>
  </required_header>
  <id_info>
    <org_study_id>9419</org_study_id>
    <nct_id>NCT02547493</nct_id>
  </id_info>
  <brief_title>Vaccination Against Pneumococcal in Naïve Abatacept Rheumatoid Arthritis Patients</brief_title>
  <acronym>VACINA</acronym>
  <official_title>Comparison of Humoral Response to Conjugate Pneumococcal Vaccine and Polysaccharide Pneumococcal Vaccine in Rheumatoid Arthritis (RA) Patients Treated With Abatacept</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Is pneumococcal conjugate vaccine (which induces a T-dependent humoral response) more
      efficient than pneumococcal polysaccharide vaccine (which induces a T-independent humoral
      response) in RA patients treated with abatacept, biotherapy targeting T-cells? The
      investigator propose to conduct a prospective, multicenter (11 centers), randomized,
      open-label study.

      The patients are going to be randomized in 2 groups: patients of the first group will be
      vaccinated with the polysaccharide pneumococcal vaccine (Pneumo23®/Pneumovax®) whereas
      patients of the second group will be vaccinated with conjugate pneumococcal vaccine
      (Prevenar13®).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study population will be all the RA patients between 18 and 85 years with instauration of
      a treatment by sub-cutaneous abatacept in association with methotrexate who agreed to
      participate to the study.

      At the time of their inclusion, patients will be randomized for receiving either pneumococcal
      polysaccharide vaccine (PPSV) or pneumococcal conjugate vaccine (PCV).

      The primary endpoint will be evaluated at one month after vaccination. The total of follow-up
      will be of 12 months.

      For the patients of the group PCV, the prime-boost strategy will be applied in order to be in
      accordance with the current French recommendation and a revaccination at 2 months after the
      initial vaccine will be realized with PPSV.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 3, 2016</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Humoral response comparison after vaccination (number of patient with at least a two-fold increase of the antibody titer for at least 3 of the 5 serotypes of interest : 1,3 14, 7F, 19A)</measure>
    <time_frame>1 month after vaccination</time_frame>
    <description>To compare the rate of responders, at one month after vaccination, between patients vaccinated with PCV and patient vaccinated with PPSV.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side Effect frequency (number of side effect at each patient's visit for both groups)</measure>
    <time_frame>1, 2,6 ans 12 months after inclusion</time_frame>
    <description>Comparison of the frequency of side effects between the 2 groups at 1, 2, 6 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prime boost strategy efficacity evaluation (number of responder in the PCV group)</measure>
    <time_frame>6 months after inclusion</time_frame>
    <description>Calculation of the rate of responders, in the PCV group, at 4 month after re-vaccination by a dose of PPSV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term immune response after vaccination</measure>
    <time_frame>6 and 12 months after vaccination</time_frame>
    <description>Comparison between the 2 groups of the rate of responders at 6 and 12 months after vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between the 2 groups of the opsonophagocytosis activity of the antibodies produced</measure>
    <time_frame>1, 2, 6 and 12 months after vaccination</time_frame>
    <description>Comparison between the 2 groups of the opsonophagocytic titers (OPA) at 1, 2, 6 and 12 months after vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumococcal vaccination predictive factor identification</measure>
    <time_frame>12 month after last patient inclusion</time_frame>
    <description>Analysis of the collected date to search for predictive factors of immune response after pneumococcal vaccination by comparison of the rates of responders within each group, according to age, gender, RA activity, MTX dosage, corticosteroid, dosage, therapeutical history</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>pneumococcal polysaccharide vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients are vaccinated vith Peumo23/Pneumovax on the first day. Abatacept started on frst day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pneumococcal conjugate vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients are vaccinated with Prevenar13 on the first day, and with Pneumo23/Pneumovax two months later.
Abatacept started on frst day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pneumococcal polysaccharide vaccine</intervention_name>
    <description>Vaccination with PPSV on first day. NB : PPSV vaccine Pneumo23 has been replaced in September 2017 by the equivalent vaccine Pneumovax because of the stop of commercialization of Pneumo23 in France by the pharmaceutical company.</description>
    <arm_group_label>pneumococcal polysaccharide vaccine</arm_group_label>
    <other_name>Pneumo23/Pneumovax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pneumococcal conjugate vaccine</intervention_name>
    <description>Patients are vaccinated with Prevenar13 on the first day, and with Pneumo23/Pneumovax two months later.</description>
    <arm_group_label>pneumococcal conjugate vaccine</arm_group_label>
    <other_name>Prevenar13</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abatacept</intervention_name>
    <description>Abatacept started on frst day</description>
    <arm_group_label>pneumococcal polysaccharide vaccine</arm_group_label>
    <arm_group_label>pneumococcal conjugate vaccine</arm_group_label>
    <other_name>Orencia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  RA according to American College of Rheumatology (ACR)/European League Against
             rheumatism (EULAR) 2010 criteria

          -  Disease Activity Score (DAS) 28 ≥ 3.2

          -  Initiation of a treatment by sub-cutaneous abatacept in combination with methotrexate
             (MTX), whatever treatment they were receiving before (apart from rituximab (RTX) in
             the last year)

          -  Patient has signed study consent form

        Exclusion Criteria:

          -  age &lt; 18 or &gt; 85 year

          -  dementia

          -  patients subjects to legal protection measures

          -  Corticosteroids ≥ 10mg/d the day of inclusion

          -  Patient who had a pneumococcal vaccination in the previous 3 years

          -  Last pneumococcal vaccination &lt; 3 year

          -  rituximab in the last year

          -  History of anaphylactic response to a vaccination

          -  Contraindications to abatacept or methotrexate

          -  Pregnancy or pregnancy wish

          -  Breast feeding

          -  Patient who currently abuse drugs or alcohol

          -  Subject who have received any live vaccines within 3 months of the anticipated first
             dose of study medication.

          -  Subject who have receive any vaccine within 1 month of the anticipated first dose of
             the study medication and for all the duration of the study

          -  Patient with contraindication to intramuscular injections

          -  Subject with respiratory insufficiency

          -  Subject at risk for Tuberculosis.

          -  Blood transfusion within the 3 months previous to the study and for all the duration
             of the study.

          -  Concomitant biologic disease-modifying antirheumatic drug (DMARD)

          -  Within 4 weeks of receiving treatment with any investigational drug.

          -  Patient positive for hepatitis B surface antigen

          -  Patient who are positive for hepatitis C antibody if the presence of hepatitis C virus
             was also shown with polymerase chain reaction or recombinant immunoblot assay.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques Morel, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU de Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacques Morel, MD PhD</last_name>
    <phone>(0)467 33 91 71</phone>
    <phone_ext>33</phone_ext>
    <email>j-morel@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHRU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <state>Hérault</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques Morel, MD PhD</last_name>
      <phone>(0)334 67 33 91 71</phone>
      <phone_ext>33</phone_ext>
      <email>j-morel@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Jacques Morel, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nord</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincent Goeb, MD PhD</last_name>
      <email>goeb.vincent@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Vincent Goeb, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thierry Schaeverbeke, MD PhD</last_name>
      <email>thierry.schaeverbeke@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Thierry Schaeverbeke, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Soubrier, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Martin Soubrier, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bicêtre</name>
      <address>
        <city>Le Kremlin-bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xavier Mariette, MD PhD</last_name>
      <email>xavier.mariette@bct.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Xavier Mariette, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Roger Salengro</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>René-Marc Flipo, MD PhD</last_name>
      <email>rene-marc.flipo@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>René-Marc Flipo, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Carémeau</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cécile Gaujoux-Viala, MD PhD</last_name>
      <email>Cecile.gaujoux.viala@chunimes.fr</email>
    </contact>
    <investigator>
      <last_name>Cécile Gaujoux-Viala, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Orléans</name>
      <address>
        <city>Orléans</city>
        <zip>45000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphanie Rist, PhD</last_name>
      <email>stephanie.rist@chr-orleans.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphanie Rist, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU La pitié salpétriere</name>
      <address>
        <city>Paris</city>
        <zip>78013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruno Fautrel, MD PhD</last_name>
      <email>bruno.fautrel@psl.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno Fautrel, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacques-Eric Gottenberg, MD PhD</last_name>
      <email>jacques-eric.gottenberg@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Jacques-Eric Gottenberg, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHPG Monaco</name>
      <address>
        <city>Monaco</city>
        <zip>98012</zip>
        <country>Monaco</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier Brocq, MD PhD</last_name>
      <email>obrocq@chpg.mc</email>
    </contact>
    <investigator>
      <last_name>Olivier Brocq, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Monaco</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2015</study_first_submitted>
  <study_first_submitted_qc>September 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2015</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccination against Pneumococcal</keyword>
  <keyword>Naïve Abatacept patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Abatacept</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

